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Oncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in
the growing arsenal of anticancer biologics. These replicating therapeutics ﬁnd favorable
conditions in the tumor niche, characterized among others by increased metabolism,
reduced anti-tumor/antiviral immunity, and disorganized vasculature. Through a self-
ampliﬁcation that is dependent on multiple cancer-speciﬁc defects, these agents exhibit
remarkable tumor selectivity. With several OVs completing or entering Phase III clinical
evaluation, their therapeutic potential as well as the challenges ahead are increasingly clear.
One key hurdle is tumor heterogeneity, which results in variations in the ability of tumors
to support productive infection by OVs and to induce adaptive anti-tumor immunity. To this
end, mounting evidence suggests tumor epigenetics may play a key role. This review will
focus on the epigenetic landscape of tumors and how it relates to OV infection.Therapeutic
strategies aiming to exploit the epigenetic identity of tumors in order to improve OV therapy
are also discussed.
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INTRODUCTION
While genetic information establishes the primary blueprint for
cellular identity, multiple regulatory layers responsive to extra and
intra-cellular signals ultimately control the manifestation of this
blueprint. Changes in cellular state, including initiation of DNA
synthesis, activation of apoptotic programs, or triggering of antivi-
ral defense mechanisms, result from an integrated response to
stimuli received by the cell. These are controlled in large part by
gene/protein expression proﬁles unique to each cell. It is now well
understood that activation of transcription factors that bind in
a DNA sequence-speciﬁc manner at promoter and enhancer ele-
ments is responsible for many of the changes in gene expression
that occur in response to environmental or developmental cues.
However transcription factors and their associated gene targets are
themselves further regulatedby the accessibility of DNAsequences.
Since the genome resides in the ﬁnite space provided by the
nucleus, it interacts with proteins known as histones to form chro-
matin and facilitate its compaction. The conﬁguration of chro-
matin compaction is modulated by epigenetic modiﬁcation and is
a key determinant for transcription factor-mediated activation of
gene transcription (Magnani et al., 2011).
Epigenetic modiﬁcations create a reversible imprint that may
be inherited through cell division. For example, DNA methylated
at promoter CpG islands is associated with gene silencing and can
be reversed by treatment with DNA methyltransferase inhibitors
such as 5-AZA (5-aza-2′-deoxycytidine) leading to the reactiva-
tion of silenced genes (Baylin and Jones, 2011; Krecmerova and
Otmar, 2012). Similarly, chromatin structure can alter accessibil-
ity to the DNA template and can be readily remodeled by histone
post-translational modiﬁcations (PTMs). PTMs including acety-
lation, methylation, phosphorylation, ubiquitination, and many
others can be added to numerous residues of histone proteins
(Bannister and Kouzarides, 2011). Different PTMs will favor chro-
matin compaction while others will increase its accessibility to
DNA binding proteins. Histone modiﬁcations and DNA methyla-
tion are highly interdependent processes and deﬁne the epigenetic
code (Cedar and Bergman, 2009). The epigenetic code is regulated
by a complex interplay of enzymatic erasers, readers, and writ-
ers that exhibit speciﬁcities toward different histones and residues
(Rice and Allis, 2001). For example, the level of histone acetyla-
tion is regulatedby the relative activity of histone acetyltransferases
(HATs) andhistone deacetylases (HDACs), proteinswith opposing
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enzymatic activities that are often found in the same protein com-
plexes (Johnsson et al., 2009; Peserico and Simone, 2010). This
also applies to histone lysinemethyltransferases (KMTs) and lysine
demethylases (KDMs). Consequently, modulating the activity of
histone-modifying enzymes can profoundly alter the epigenetic
proﬁle of a cell (Egger et al., 2004; Yoo and Jones, 2006).
Given their critical role in the regulation of normal cellular
physiology, it is not surprising that aberrations in epigenetic mod-
iﬁcations can contribute to the manifestations of human disease.
For example, a cell’s epigenetic proﬁle can impact the progression
of acute microbial diseases (discussed in more detail below) as
well as the development and treatment of chronic diseases such
as cancer. DNA hypermethylation is often observed in cancer cells
(Patel et al., 2012). The genome-wide distribution of histonemod-
iﬁcations can also be altered in the course of cancer development
(Akhtar-Zaidi et al., 2012; Magnani et al., 2013). As well, the activ-
ity of various histone-modifying enzymes can be altered through
mutations (Taylor et al., 2011), aberrant expression (Schildhaus
et al., 2011; Bennani-Baiti et al., 2012) and/or recruitment to tar-
get histone residues via oncogenic fusion proteins (Lubieniecka
et al., 2008). Consequently, many cancers are sensitive to epi-
genetic modulators such as 5-AZA, HDAC, or KDM inhibitors
(Hurtubise et al., 2008; Taylor et al., 2011; Schenk et al., 2012)
and epigenetic modiﬁcations have been shown to inﬂuence the
response to chemotherapy (Glasspool et al., 2006; Magnani et al.,
2013).
ONCOLYTIC VIROTHERAPY
While epigenetic modulators hold promise as anticancer agents, it
is clear that like for many other cancer therapies, tumor-speciﬁcity
is of paramount importance. Tremendous efforts have been made
over the past decades to tackle the difﬁcult task of developingmore
selective cancer therapies, aiming to exploit the sometimes-subtle
differences between normal tissues and tumors. One promising
new class of therapeutics comes to us from the ﬁeld of virology.
Since the early 1900s it has been observed that cancers can be
uniquely susceptible to virus infection (Dock, 1904). While the
ﬁrst clinical trials using replication-competent viruses to treat can-
cer began in the seventies (Asada, 1974; Kelly and Russell, 2007;
Pol et al., 2013), approval of the ﬁrst oncolytic virus (OV) is only
now in the foreseeable future in North America (Carroll, 2011;
Galanis et al., 2012; Heo et al., 2013). The more recent clinical
success of OVs is in large part due to our more complete under-
standing of the molecular biology of both cancer cells and viruses
that allowed us to create virus strains with improved selectivity
and anti-tumor activity, and clinical safety proﬁle (Breitbach et al.,
2011). Rapid proliferation and deregulated metabolism (Fritz and
Fajas, 2010), disorganized vasculature (Jain, 2005), and defective
antiviral innate immune responses (Dunn et al., 2006) in malig-
nant tumors are hallmarks that not only deﬁne cancer, but also
favor viral growth. Building on these observations, several OVs
have been engineered or selected to take advantage of one or more
of these features (Russell et al., 2012). A variety of OV platforms
are currently under clinical evaluation including those based on
herpes simplex virus (HSV), Reovirus, vaccinia virus (VV), Ade-
novirus, Measles virus, and vesicular stomatitis virus (VSV; U.S.
National Library of Medicine, 2013).
ONCOLYTIC VIROTHERAPY AND THE CELLULAR INNATE
ANTIVIRAL RESPONSE
It is now well established that cancer cells that evolve to frank
malignancies often acquire defects in their ability to mount a suc-
cessful antiviral response and this attribute/deﬁcit contributes to
the selectivity of many if not allOVs (NormanandLee,2000; Stojdl
et al., 2000, 2003). This is often a consequence of the observation
that approximately 65–70% of tumors are unable to produce or
respond to type I interferon (IFN), a key mediator of the cellu-
lar antiviral response (Stojdl et al., 2003; Dunn et al., 2006). IFNs
are antiviral cytokines induced following recognition of viral pro-
teins and nucleic acids by cellular pattern recognition receptors
such as Toll-like receptors (TLRs) that signal through to transcrip-
tion factors such as interferon regulatory factors (IRFs). There are
many isoforms of IFN,which can be functionally sub-divided in at
least three types (types I/II/III). While type I/III IFNs (e.g., IFN-α,
IFN-β/IFN-λ) stimulate cellular antimicrobial immunity; type II
IFNs (e.g., IFN-γ) coordinate the host immune response. IFNs
elicit their transcriptional effects through autocrine and paracrine
activation of IFN receptors and signaling through the Jak/STAT
signaling pathway (Borden et al., 2007). This induces the tran-
scriptional up-regulation of interferon-stimulated genes (ISGs),
many of which have direct antiviral/pro-apoptotic activities (e.g.,
RNAseL, TNF-α, TRAIL) and/or immune-stimulatory properties
(e.g., components of major histocompatibility complex).
ONCOLYTIC VIRUSES AND THE GENERATION OF AN
ANTI-TUMOR IMMUNE RESPONSE
In addition to taking advantage of a niche provided by aberra-
tions unique to cancer and the tumor microenvironment, OVs
have been used as platforms to express a range of therapeutic
transgenes, from suicide genes to immune-stimulatory cytokines
(Merrick et al., 2009; Maldonado et al., 2010; Chai et al., 2012;
Stephenson et al., 2012; Lange et al., 2013). In this regard, it is now
well recognized that beyond simply lysing infected tumor cells,
OVs effectively “de-cloak” tumors by stimulating immune cells to
recognize cancer antigens, ultimately leading to tumor destruc-
tion and in some cases, long-term cures (Sobol et al., 2011; Huang
et al., 2012). Many tumors evade immune recognition due to a
dysfunctional antigen presentation pathway, which is under tight
multilayered transcriptional control ultimately dictated by type
I/II IFNs and the class II transactivator (CIITA). This transcrip-
tion factor controls the expression of numerous genes involved
in antigen presentation, including class I and II MHC molecules,
which display tumor or pathogen derived peptides to killer T cells
(CD4+/CD8+; LeibundGut-Landmann et al., 2004).
The antigenpresentationpathway is inﬂuencedbyboth tumori-
genesis and OV therapy. Many tumor cells including leukemias,
lymphomas, and carcinomas, avoid immune recognition due to a
dysfunctional antigen presentation pathway, largely caused by epi-
genetic silencing (e.g., histone deacetylation or DNA methylation)
of MHC2TA, the gene encoding CIITA (LeibundGut-Landmann
et al., 2004). OV therapies can enhance tumor-associated anti-
gen presentation through various mechanisms. In response to OV
infection, type I and II IFN secretion by infected cells within the
tumor environment (which also includes normal tumor inﬁltrat-
ing cells) leads to the up-regulation of hundreds of ISGs including
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IRF-1, which up-regulates CIITA expression (Muhlethaler-Mottet
et al., 1998). Notably, this response is dependent upon the abil-
ity to respond to IFN, which can be limited in many cancer cells
(Stojdl et al., 2003; Dunn et al., 2006).
Oncolytic virotherapy can have a positive inﬂuence on antigen
presentation and the anti-tumor response. Some OVs including
HSV, reovirus, and measles virus, induce syncytia formation in
infected and neighboring cells. These large multinucleated tumor
cells secrete an abundance of “syncytiosomes,”which are exosome-
like vesicles that present tumor-associated antigens via MHC
molecules (Bateman et al., 2000, 2002). Finally, destruction of can-
cer cells following infection by OVs provides an additional source
of tumor antigens available for capture by antigen-presenting
immune cells. The immunostimulatory nature of the virus itself,
through activation of TLRs and subsequent cellular produc-
tion of pro-inﬂammatory cytokines stimulates the recruitment
of antigen-presenting cells that sample tumor-derived and virus-
expressed antigens. Presentation of tumor antigens to killer T
cells (CD4+/CD8+) through MHC molecules in the presence of
inﬂammatory cytokines can thus lead to generation of a robust
and long-lasting immune responses directed against the tumor.
To capitalize on these beneﬁcial immunological effects, some
groups have developed OV/vaccine hybrid strategies. These strate-
gies are designed speciﬁcally to re-educate the adaptive immune
system to recognize and respond to tumor antigens. Thus,OVs can
be engineered to express not only immune-stimulatory cytokines
but also tumor-speciﬁc antigens to further stimulate an anti-tumor
immune response following OV infection of cancer cells (Diaz
et al., 2007; Pulido et al., 2012). Indeed, several studies have shown
that this “tumor antigen vaccination” effect can be further ampli-
ﬁed using a prime-boost strategy, by priming with an antigen then
boosting the response using an OV expressing the same antigen
(Bridle et al., 2010, 2013). As discussed below, it is possible to use
epigenetic modiﬁers to further ﬁne-tune this oncolytic vaccine
approach. It is also possible to take advantage of this vaccine effect
by infecting cancer cells ex vivo and re-injecting the inactivated
“oncolysate” to generate prophylactic and even therapeutic anti-
cancer immune responses. The resulting up-regulation of MHCs
and co-regulatory factors and presentation of tumor antigens at
the surface of OV infected cells as well as the presence of immune-
stimulating virus is thought to be at the root of this effect (Lemay
et al., 2012). Overall, these studies emphasize the important role
of antigen expression/presentation inOV-stimulated anti-tumoral
responses.
TUMOR HETEROGENEITY: INHERENT BARRIER TO OV
THERAPY
Despite promising clinical data, it is clear that there is considerable
inter- (and likely intra-) tumor heterogeneity in the responsive-
ness to OV therapy in vitro as well as in vivo in both pre-clinical
and clinical settings (Breitbach et al., 2011; Sobol et al., 2011).
Because overcoming the innate cellular antiviral response and
generating a robust anti-tumor response are critical to observe
meaningful therapeutic beneﬁts from oncolytic virotherapy, it is
important to understand what tumorigenic processes inﬂuence
these closely linked pathways in order to manipulate them to
improve therapeutic outcomes.
Given the profound epigenetic divergence that prevails in
tumor cells (Akhtar-Zaidi et al., 2012; DeCarvalho et al., 2012), it is
foreseeable that tumor-speciﬁc gene expression response proﬁles
induced by virus infection may be altered by epigenetic modi-
ﬁcations and that this could contribute to the heterogeneity of
tumor responsiveness to OVs. As discussed previously, epigenetic
reprogramming is well known to play an important role in onco-
genic transformation and numerous reviews extensively cover the
role of epigenetics in cancer (Muntean and Hess, 2009; Baylin
and Jones, 2011; Hatziapostolou and Iliopoulos, 2011; Suva et al.,
2013). Thus, the remainder of this review aims to highlight cur-
rent knowledge of genes epigenetically regulated in cancer that are
also involved in pathways critical for OV therapy, namely the IFN-
mediated antiviral response and antigen presentation (Table 1),
and how this contributes to tumor heterogeneity (Figure 1).
THE ROLE OF EPIGENETICS IN HOST SUSCEPTIBILITY TO
VIRAL INFECTION
Epigenetic regulation of innate and adaptive immune processes is
emerging as a key determinant of susceptibility to viral infection.
Several reports suggest that cell type-speciﬁc epigenetic regulation
of antiviral ISGs leads to differences in permissibility to virus infec-
tions in both normal and tumor cells (Naka et al., 2006; Nguyen
et al., 2008; Fang et al., 2012; Chen et al., 2013; Cho et al., 2013).
Recently, histone H3K9 di-methylation, a repressive heterochro-
matin mark, was found to be elevated within IFN genes and ISGs
in non-professional IFN-producing cells (e.g., ﬁbroblasts) as com-
pared to professional IFN-producing plasmacytoid dendritic cells
(pDCs). Interestingly, inhibiting the KMT G9a by both genetic
and pharmacological means led to increased IFN production and
responsiveness in ﬁbroblasts. In line with this, G9a-ablated ﬁbrob-
lastswere also renderedmore resistant to infectionby viruses (Fang
et al., 2012; Figure 1).
Another recent study in mice harboring the murine viral sus-
ceptibility locusTmevp3 revealed the intriguing role of NeST,a long
non-coding RNA (lncRNA) adjacent to the IFN-γ locus in both
mice and humans (Vigneau et al., 2001). NeST was found to func-
tion as an epigenetically driven enhancer element (Gomez et al.,
2013) leading to increased IFN-γ production in mouse CD8+ T
cells by directly interacting with the H3K4 histone methyltrans-
ferase complex and increasing H3K4 trimethylation, an activating
mark. This novel epigenetic modiﬁcation culminated in height-
ened susceptibility to persistent viral infection in mice (Gomez
et al., 2013; Figure 1). Although the role of NeST in human
epigenetic regulation is currently unknown, it is likely lncR-
NAs contribute to epigenetic regulation and manifestation of cell
phenotypes includingpermissiveness to virus infection and cancer.
CANCER EPIGENETICS IMPACT THE REGULATION OF
ANTIVIRAL RESPONSE GENES
As previously discussed, the majority (but not all) of cancer cells
are dysfunctional in their ability to produce and/or respond to
IFN (Dunn et al., 2006). While crosstalk between oncogenic sig-
nals and the antiviral response pathways have been shown to play
a role (Farassati et al., 2001; Shmulevitz et al., 2005); epigenetic
events are also likely contributors to this phenotype. One indica-
tion of this comes from a series of studies on cells derived from
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Table 1 | Epigenetic control: implications in cancer and OV therapy.
Genetic target Cellular function Epigenetic
modification
Cell type Reference
ISGs (IFI27, 9–27,
LMP2, LMP7, Viperin,
IFI44, IFIT2, ISG56 )
Antiviral response DNA hypermethylation Huh-7 cells (Human
hepatoma)
Naka et al. (2006)
STAT1, ISGs (IFI27,
IRG1, Viperin, Cxcl10,
ISG15, IFI44)
Antiviral response,
anti-tumor response,
antigen presentation
Histone deacetylation Human cortical neurons Cho et al. (2013)
CREB3LI, MX1 Antiviral response DNA hypermethylation Human hepatoma Huh-7
cells
Chen et al. (2013)
IFN-β, ISGs (MX1, IFIT1,
among many)
Antiviral response H3K9 dimethylation Mouse embryonic
ﬁbroblasts, mouse
splenic dendritic cells
Fang et al. (2012)
IFN-γ Antiviral response,
anti-tumor response
H3K4 trimethylation Mouse CD4+/CD8+ T
cells
Gomez et al. (2013)
IRF7, IFN regulated genes IFN-β induction, antiviral
response
DNA hypermethylation Li-Fraumeni immortalized
cells
Fridman et al. (2006)
IRF7, IFITM1, OAS1, OAS2,
STAT1, MX1, TIP30, IL-8,
TRAIL, HLA-F, HLA class I
locus C heavy chain,
among others
IFN-α/β induction,
antiviral response,
anti-tumor response,
antigen presentation
DNA hypermethylation Li-Fraumeni immortalized
cells
Kulaeva et al. (2003)
IRF7 IFN-α/β induction DNA hypermethylation Li-Fraumeni immortalized
cells
Li et al. (2008)
IRF8 IFN signaling,
differentiation, apoptosis,
tumor suppression
DNA hypermethylation Nasopharyngeal,
esophageal, breast, and
cervical primary
carcinomas
Lee et al. (2008)
IRF4, IRF5, IRF8 IFN signaling,
differentiation, apoptosis
signaling, tumor
suppression
DNA hypermethylation Gastric carcinoma Yamashita et al. (2010)
STAT1, STAT2, and STAT3 Antiviral response,
antigen presentation,
anti-tumor response
DNA hypermethylation Colon carcinoma Karpf et al. (1999)
JAK1 kinase Antiviral response,
antigen presentation,
anti-tumor response
DNA hypermethylation,
histone deacetylation
Prostate
adenocarcinoma
Dunn et al. (2005)
Apo2L/TRAIL receptor 1
(DR4), RASSFIA, XAF1,
TRAIL
TRAIL-mediated
apoptosis
DNA hypermethylation Melanoma cell lines,
renal carcinoma,
experimentally
transformed human cell
lines
Reu et al. (2006a,b), Bae
et al. (2008), Lund et al.
(2011)
unknown TRAIL-mediated
apoptosis
Histone deacetylation Medulloblastoma Hacker et al. (2009)
(Continued)
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Table 1 | Continued
Genetic target Cellular function Epigenetic
modification
Cell type Reference
IFITM1 Antiviral response DNA hypermethylation Gastric carcinoma Lee et al. (2012)
ISGs (Global regulation) Antiviral response,
Anti-tumor response
Histone deacetylation U2OS (osteosarcoma),
HeLa (cervical
carcinoma)
Chang et al. (2004)
ISGs under ISRE control Antiviral response,
Anti-tumor response
Histone deacetylation Human foreskin
ﬁbroblasts
Sakamoto et al. (2004)
IFN-β, FGF2, VEGFC,
CASP1, CASP9, ISGs
(OAS2, MyD88, IFIT1,
ISG15, TGFB1, IRF7, IL-8,
among others)
Antiviral response,
Angiogenesis, Apoptosis
Histone deacetylation Human fetal microglia,
astrocytes
Suh et al. (2010)
STAT-1 dependent genes,
ISGs
Antiviral response,
apoptosis, anti-tumor
response
Histone deacetylation Colorectal carcinoma
cells; L929 cells (mouse
ﬁbroblasts)
Génin et al. (2003),
Klampfer et al. (2004)
2′–5′ OAS, ISG54, IFITM3,
IP-10
Antiviral response Histone deacetylation 2fTGH (sarcoma) cells Nusinzon and Horvath
(2003)
CIITA Antigen presentation Histone deacetylation Mouse plasmacytoma
cells; squamous cell
carcinoma;
rhabdomyosarcomas
Kanaseki et al. (2003),
Chou (2005), Londhe
et al. (2012)
unknown Antigen presentation Histone deacetylation Mouse plasmacytomas Khan et al. (2004)
CIITA Antigen presentation H3K27 trimethylation Uveal melanoma cells,
breast cancer cells
Holling et al. (2007), Truax
et al. (2012)
CIITA Antigen presentation DNA hypermethylation Head and neck cancer
cells, choriocarcinoma
cells, uveal melanoma,
colorectal and gastric
carcinomas
Morris et al. (2000),
Satoh et al. (2004),
Radosevich et al. (2007),
Meissner et al. (2008)
CIITA Antigen presentation Histone deacetylation,
DNA hypermethylation
Myeloid leukemia Morimoto et al. (2004)
TAP-1 Antigen presentation Histone H3 acetylation Carcinomas Setiadi et al. (2007)
Numerous reports have cited instances of epigenetic modulation affecting permissibility to virus infection, many of which occur in tumor cells. Here we present a
summary of these reports, listing the genetic target and its cellular function, the epigenetic modiﬁcation, and the cell type involved. IFN, interferon; ISG, interferon
stimulated gene; IFI, IFN alpha inducible protein; LMP, low molecular weight polypeptide; STAT, signal transducer and activator of transcription; CXCL1, C-X-C motif
ligand 1; CREB3L1, cAMP responsive element binding protein 3 like-1; MX1, myxovirus resistance 1; IFIT1, interferon-induced protein with tetratricopeptide repeats
1; IRF, IFN regulatory factor; OAS, 2′–5′ oligoadenylate synthetase; TIP30, TAT-interacting protein 30; IL, interleukin; TRAIL, tumor necrosis factor- related apoptosis-
inducing ligand; HLA, human leukocyte antigen; JAK1, janus kinase 1; DR4, Apo2/TRAIL receptor 4; XAF1, x-linked inhibitor of apoptosis-associated factor 1; ISRE,
IFN sensitive response element; FGF2, ﬁbroblast growth factor 2; VEGFC, vascular endothelial growth factor C; CASP, caspase; TGFB1, transforming growth factor
beta 1; CIITA, Class II MHC transactivator; TAP-1, transporter 1, ATP-binding cassette, sub-family B.
cancer-prone Li-Fraumeni syndrome patients. Cells from these
patients spontaneously immortalize when serially passaged in tis-
sue culture due tomutations in the tumor suppressor p53, however
transformation is inhibited upon treatment with 5-AZA (Kulaeva
et al., 2003; Fridman et al., 2006). DNA methylation proﬁling of
these immortalized cells revealed hypermethylation at the pro-
moters of numerous genes involved in the type I IFN pathway,
including IRF7 (Kulaeva et al., 2003; Fridman et al., 2006; Li et al.,
2008). Interestingly, these immortalized Li-Fraumeni patient-
derived cells were inherently more sensitive to VSV infection
(Fridman et al., 2006; Figure 1).
Indeed, epigenetic repression of IFN and associated genes cor-
relates with IFN insensitivity in many cancers. IRFs 4, 5, 7, and
8 are the target of DNA methylation, leading to dysfunctional
responsiveness to type I and II IFNs in gastric cancer (Yamashita
et al., 2010), while IRF8 is silenced by the same mechanism in
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FIGURE 1 | Impact of cancer epigenetics on oncolytic virotherapy.
The integration of repressive epigenetic marks such as DNA CpG methylation
(Me, circle ﬂags) and histone H3K9 methylation (Me, square ﬂags), and
activating epigenetic marks such as histone H3K4 methylation and histone
H3K27 acetylation (Ac, square ﬂags) lead to higher-order nucleosome
packaging and repression (red ﬂags) or open chromatin and gene expression
(green ﬂags). In cancer cells, dysregulation of epigenetic processes leads to
various possible epigenetic states with respect to genes involved in the
antiviral response (e.g., type I IFN, interferon stimulated genes or ISGs) as
well as those involved in antigen presentation (e.g., MHC I/II expression,
represented by a semi-circle at the end of a stick). This ultimately leads to a
variety of cancer cell phenotypes (A–D) and subsequently, a variety of
potential therapeutic responses to oncolytic viruses (OVs, represented by
spiked green circles).
several carcinomas (Lee et al., 2008). Similarly, IFN responsiveness
was found to be suppressed in colon carcinoma cells due to DNA
methylation at STAT1, STAT2, and STAT3, which can be restored
following5-AZA treatment (Karpf et al.,1999; Figure 1). Along the
same signaling axis, epigenetic silencing of JAK1 in prostate ade-
nocarcinoma cells was associated with unresponsiveness to both
type I and type II IFNs (Dunn et al., 2005).
IFN-induced apoptosis is mediated by ISGs including
Apo2L/TRAIL, which are also often dysfunctional in cancers (Reu
et al., 2006b; Borden, 2007; Bae et al., 2008; Burton et al., 2013).
Genes involved in Apo2L/TRAIL signaling, including TRAIL,
the TRAIL receptor DR4, RASSF1A, and XAF1 are epigeneti-
cally silenced in melanomas (Reu et al., 2006a,b; Bae et al., 2008),
leukemia (Soncini et al., 2013), renal carcinoma (Reu et al., 2006a)
and experimentally transformed cells (Lund et al., 2011). Inter-
estingly, 5-AZA treatment can restore TRAIL-mediated apoptosis
induced by type I and II IFN (Reu et al., 2006a,b; Bae et al., 2008;
Lund et al., 2011; Soncini et al., 2013; Figure 1). However, this cell
death pathway is likely also epigenetically silenced through histone
PTMs given that in medulloblastoma, IFN-γ could induce apop-
tosis via TRAIL only following treatment with theHDAC inhibitor
valproic acid (Hacker et al., 2009).
Overall, these studies highlightmultiple epigeneticmechanisms
that transcriptionally repress IFN-associated genes, culminating
in dysfunctional and non-responsive IFN signaling across various
cancer subtypes. However, in some instances alterations to epige-
netic modiﬁcations in cancer lead to the up-regulation of antiviral
factors. In both gastric tumors and gliomas, overexpression of the
ISG IFITM1 promotes cancer cell migration and invasion, and its
elevated expression is linked to reduced CpG methylation levels
(Yu et al., 2011; Lee et al., 2012). Alongside its oncogenic proper-
ties, IFITM1 has antiviral properties, through its ability to inhibit
viral membrane fusion (Li et al., 2013; Figure 1).
It is also notable that while most cancers display IFN pathway
defects, approximately a third of cancer cells are fully functional
in their ability to produce and respond to IFN (Stojdl et al.,
2003; Norman and Lee, 2000). Importantly, several studies have
shown thatHDAC inhibition using a variety of chemical inhibitors
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modulate IFN-induced expression of ISGs, type I IFN, andTLR3/4
(Génin et al., 2003; Nusinzon and Horvath, 2003; Chang et al.,
2004; Klampfer et al., 2004; Sakamoto et al., 2004; Suh et al., 2010),
which leads to increased OV activity in resistant cells (Nguyen
et al., 2008). This further highlights the key role of epigenetic
regulation in the generation of an antiviral response and sug-
gests that it may be possible to improve OV efﬁcacy in resistant
tumors by manipulating the cancer epigenome as will be discussed
shortly.
CANCER CELLS EPIGENETICALLY REGULATE GENES
INVOLVED IN ANTIGEN PRESENTATION
In addition to inactivating the antiviral response to escape anti-
proliferative/pro-death signals, tumors must also evade immune
recognition and clearance. To this end, many tumor types epi-
genetically suppress CIITA expression by mechanisms including
histone deacetylation/methylation and DNA promoter methyla-
tion, resulting in suppressed IFN-γmediated MHC-I and MHC-II
gene expression and dysfunctional antigen presentation (Morris
et al., 2000; Kanaseki et al., 2003; Morimoto et al., 2004; Satoh
et al., 2004; Chou, 2005; Holling et al., 2007; Radosevich et al.,
2007; Meissner et al., 2008; Londhe et al., 2012; Truax et al., 2012;
Figure 1). Interestingly, treatment of cancer cells with HDAC
inhibitors canpromote antigenpresentation andultimately help to
induce anti-tumor immunity (Khan et al., 2004; Chou, 2005). For
example, trichostatin A (TSA)-treated irradiated B16 melanoma
cells administered prophylactically as a cancer vaccine are signiﬁ-
cantlymore effective then control irradiated B16 cells at protecting
from a subsequent challenge with live B16 tumor cells (Khan
et al., 2007). Cancer immune evasion can also be mediated by
dampened expression of the transporter associated with anti-
gen processing 1 (TAP1), a key factor for antigen presentation
by MHC molecules (Johnsen et al., 1999). In carcinoma cells,
decreased TAP1 expression was attributed to reduced levels of
histone H3 acetylation at the TAP-1 promoter (Setiadi et al., 2007;
Figure 1).
In addition to these direct epigenetic effects on components of
the antigenic response within cancer cells, the tumor microen-
vironment has also been shown to epigenetically drive tumor
inﬁltrating CD4+ T cells to tolerance. In colon cancer, inﬁltrating
CD4+ lymphocytes displayed high levels of DNA methylation at
the IFN-γ promoter, and consequently required treatment with
5-AZA to enable tumor antigen-stimulated IFN-γ production
(Janson et al., 2008; Figure 1). Overall, these studies highlight the
role of epigenetic control in conferring “stealth” status to tumor
cells such that they may evade the immune surveillance.
HDAC INHIBITORS CAN ALTER SUSCEPTIBILITY TO
ONCOLYTIC VIRUSES
As alluded to earlier, defects in the IFN pathway are common in
many malignancies but a signiﬁcant proportion of tumors retain
an active antiviral response (Stojdl et al., 2003; Dunn et al., 2006).
Overcoming this antiviral response has been identiﬁed as a key bar-
rier to the success of OV therapy and is the focus of many research
groups including our own (Parato et al., 2005; Chiocca, 2008;
Diallo et al., 2010; Liikanen et al., 2011; Russell et al., 2012). To
overcome this barrier, many groups have looked at the possibility
of using HDAC inhibitors in combination with OV therapy due to
their repressive effects on the IFN-mediated antiviral response.
In one of the earliest reports, the anti-tumor effect of oncolytic
adenovirus (OBP-301) in human lung cancer cells was found to
synergize with FR901228 (Romidepsin), a class I HDAC inhibitor
(Watanabe et al., 2006). However, in this report, increased activ-
ity was attributed to the upregulation of coxsackie adenovirus
receptor (CAR) expression in cancer cells as opposed to direct
effects on the antiviral response. Intriguingly, valproic acid, a
class I/II HDAC inhibitor was found by another group in par-
allel to inhibit oncolytic adenovirus through the up-regulation
of p21 (WAF1/CIP1; Hoti et al., 2006). Subsequently, TSA and
valproic acid, two pan-HDAC inhibitors were found to enhance
HSV oncolysis in squamous cell carcinoma and glioma cells
(Otsuki et al., 2008; Katsura et al., 2009). Around the same
time, Nguyen et al. (2008) showed that several HDIs could syn-
ergize with the oncolytic VSV-51, an attenuated oncolytic
VSV-mutant that is incapable of blocking IFN production (Stojdl
et al., 2003). Combination treatment with HDIs resulted in syn-
ergistic cell killing, due to both enhanced induction of cell death
and increased viral output (typically over 100-fold). Enhanced
viral spreading of VV and semliki forest virus (SFV) was also
observed in this study. Subsequent to this, TSA was shown to
be particularly effective for improving VV-based OVs in several
resistant cancer cell lines in vitro and in subcutaneous xenograft
and syngeneic lung metastasis mouse models (MacTavish et al.,
2011). Importantly, the impacts of HDAC inhibitors on OV
spread and efﬁcacy remain restricted to tumors and not nor-
mal cells, presumably because cancer cells exhibit a number of
additional aberrations, such as increased metabolism, that pro-
mote viral growth independent of the status of the antiviral
response.
HDAC INHIBITORS AS MODULATORS OF ONCOLYTIC
VIRUS-ASSOCIATED ANTI-TUMOR IMMUNITY
While initial experiences with HDAC inhibitors in combina-
tion with OVs exploited mainly the ability of these epigenetic
modiﬁers to improve the infectivity of resistant tumors, at least
in part by dampening the innate cellular antiviral response,
more recent studies have further exploited the broader immuno-
logical effects of HDAC inhibitors. For example, one report
showed that valproic acid suppresses NK cell activity by blocking
STAT5/T-BET signaling leading to enhanced oncolytic HSV activ-
ity (Alvarez-Breckenridge et al., 2012). Also of note, a recent report
by Bridle et al. (2013) demonstrated signiﬁcant improvements
in the generation of an anti-tumor immune response elicited
against aggressive melanoma following a heterologous prime-
boost vaccination strategy. After the establishment of intracranial
melanomas, immune-competent mice were primed with a non-
replicating adenovirus expressing the dopachrome tautomerase
(hDCT) melanoma antigen, and then boosted with oncolytic VSV
expressing hDCT. While this prolonged survival, mice were fully
cured (64%) onlywhenVSV-hDCTwas administered in combina-
tionwith the class IHDAC inhibitorMS-275. Remarkably,MS-275
reduced VSV-speciﬁc neutralizing antibodies and memory CD8+
Tcellswhilemaintainingprime-induced levels of humoral and cel-
lular immunity against the tumor antigen. Interestingly, MS-275
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also ablated autoimmune vitiligo typically observed following
immunization against the melanocyte-expressed antigen (Bridle
et al., 2013).
USE OF OTHER EPIGENETIC MODULATORS TO IMPROVE
ONCOLYTIC VIROTHERAPY?
Given the epigenetic regulation of the antiviral response and anti-
gen presentation pathways, it is tempting to speculate that other
epigenetic modulators, in addition to HDAC inhibitors, may also
be used to amplify therapeutic responses in combination with
OVs. To this end, a recent study by Okemoto et al. (2012) showed
that 5-AZA treatment could enhance HSV replication when co-
administered with IL-6 (Figure 1). However, given numerous
reports of cancers epigenetically silencing antiviral genes by DNA
methylation (Table 1), we would expect that in general 5-AZA
and other DNA methyltransferase inhibitors should be ineffec-
tive at overcoming the cellular antiviral response. On the other
hand, the advent of new pharmacological inhibitors of KMTs and
KDMs brings forth new possibilities for improving OV efﬁcacy.
For example, given the ﬁnding that histone H3K9 dimethyla-
tion observed at ISGs correlates with repression and reduced IFN
response/expression, investigating the potential utility of H3K9-
demetylase inhibitors for enhancingOV spread in resistant tumors
seems warranted. However, it is of critical importance that, as
is observed for HDAC inhibitors, OV-enhancing effects remain
tumor-selective.
CONCLUSION
While genetic mutations are believed to be essential initiators
of carcinogenesis, it is clear that epigenetic deregulation plays
a key role in augmenting and/or maintaining the tumor phe-
notype. OVs are promising biotherapeutics that among others
take advantage of the epigenetic silencing of cellular antiviral
response genes and in many ways unmask cancer antigens as they
destroy cancer cells and promote an inﬂammatory response.While
additional studies on the impact of epigenetic regulation on the
antiviral and immunological responses are needed, it is already
recognized from studies using HDAC inhibitors that epigenetic
modulators can positively impact OV efﬁcacy. Additional in vitro
and in vivo studies evaluating the effect of other epigenetic mod-
ulators are needed to determine whether these could be used in
combination with promising OV platforms anticipated to reach
the clinic in the near future, to further improve their therapeutic
impact.
ACKNOWLEDGMENT
This work was supported by grants from the Terry Fox Research
Institute (Jean-Simon Diallo and John C. Bell).
REFERENCES
Akhtar-Zaidi, B., Cowper-Sal-Lari, R.,
Corradin, O., Saiakhova, A., Bar-
tels, C. F., Balasubramanian, D., et al.
(2012). Epigenomic enhancer pro-
ﬁling deﬁnes a signature of colon
cancer. Science 336, 736–739. doi:
10.1126/science.1217277
Alvarez-Breckenridge, C. A., Yu, J.,
Price, R., Wei, M., Wang, Y., Now-
icki, M. O., et al. (2012). The his-
tone deacetylase inhibitor valproic
acid lessens NK cell action against
oncolytic virus-infected glioblastoma
cells by inhibition of STAT5/T-BET
signaling and generation of gamma
interferon. J. Virol. 86, 4566–4577.
doi: 10.1128/JVI.05545-11
Asada, T. (1974). Treatment of human
cancer with mumps virus. Cancer 34,
1907–1928. doi: 10.1002/1097-
0142(197412)34:6<1907::AID-
CNCR2820340609>3.0.CO;2-4
Bae, S. I., Cheriyath, V., Jacobs, B.
S., Reu, F. J., and Borden, E.
C. (2008). Reversal of methylation
silencing of Apo2L/TRAIL receptor
1 (DR4) expression overcomes resis-
tance of SK-MEL-3 and SK-MEL-28
melanoma cells to interferons (IFNs)
or Apo2L/TRAIL. Oncogene 27, 490–
498. doi: 10.1038/sj.onc.1210655
Bannister, A. J., and Kouzarides, T.
(2011). Regulation of chromatin by
histone modiﬁcations. Cell Res. 21,
381–395. doi: 10.1038/cr.2011.22
Bateman, A., Bullough, F., Murphy, S.,
Emiliusen, L., Lavillette, D., Cosset, F.
L., et al. (2000). Fusogenicmembrane
glycoproteins as a novel class of genes
for the local and immune-mediated
control of tumor growth. Cancer Res.
60, 1492–1497.
Bateman, A. R., Harrington, K. J.,
Kottke, T., Ahmed, A., Melcher,
A. A., Gough, M. J., et al. (2002).
Viral fusogenic membrane glycopro-
teins kill solid tumor cells by non-
apoptotic mechanisms that promote
cross presentation of tumor antigens
by dendritic cells. Cancer Res. 62,
6566–6578.
Baylin, S. B., and Jones, P. A. (2011).
A decade of exploring the cancer
epigenome – biological and transla-
tional implications. Nat. Rev. Cancer
11, 726–734. doi: 10.1038/nrc3130
Bennani-Baiti, I. M., Machado, I.,
Llombart-Bosch, A., and Kovar, H.
(2012). Lysine-speciﬁc demethylase
1 (LSD1/KDM1A/AOF2/BHC110)
is expressed and is an epigenetic
drug target in chondrosarcoma,
Ewing’s sarcoma, osteosarcoma,
and rhabdomyosarcoma. Hum.
Pathol. 43, 1300–1307. doi:
10.1016/j.humpath.2011.10.010
Borden, E. C. (2007). Augmentation
of effects of interferon-stimulated
genes by reversal of epigenetic
silencing: potential application
to melanoma. Cytokine Growth
Factor Rev. 18, 491–501. doi:
10.1016/j.cytogfr.2007.06.022
Borden, E. C., Sen, G. C., Uze, G.,
Silverman, R. H., Ransohoff, R. M.,
Foster, G. R., et al. (2007). Inter-
ferons at age 50: past, current, and
future impact on biomedicine. Nat.
Rev. Drug Discov. 6, 975–990. doi:
10.1038/nrd2422
Breitbach, C. J., Burke, J., Jonker, D.,
Stephenson, J., Haas, A. R., Chow,
L. Q., et al. (2011). Intravenous
delivery of a multi-mechanistic
cancer-targeted oncolytic poxvirus in
humans. Nature 477, 99–102. doi:
10.1038/nature10358
Bridle, B. W., Chen, L., Lemay, C.
G., Diallo, J.-S., Pol, J., Nguyen,
A., et al. (2013). HDAC inhibi-
tion suppresses primary immune
responses, enhances secondary
immune responses, and abro-
gates autoimmunity during tumor
immunotherapy. Mol. Ther. 21,
887–894. doi: 10.1038/mt.2012.265
Bridle, B. W., Stephenson, K. B.,
Boudreau, J. E., Koshy, S., Kazdhan,
N., Pullenayegum, E., et al. (2010).
Potentiating cancer immunother-
apy using an oncolytic virus.
Mol. Ther. 18, 1430–1439. doi:
10.1038/mt.2010.98
Burton, T. R., Henson, E. S., Azad,
M. B., Brown, M., Eisenstat, D. D.,
and Gibson, S. B. (2013). BNIP3
acts as transcriptional repressor of
death receptor-5 expression and pre-
vents TRAIL-induced cell death in
gliomas. Cell Death Dis. 4, e587. doi:
10.1038/cddis.2013.100
Carroll, J. (2011). Amgen bets $1B
on BioVex’s dual-mechanism cancer
therapy. Fierce Biotech. Available at:
http://www.ﬁercebiotech.com/story/
amgen-bets-1b-biovexs-dual-mech-
anism-cancer-therapy/2011-01-25
(accessed April 3, 2013).
Cedar, H., and Bergman, Y. (2009).
Linking DNA methylation and
histone modiﬁcation: patterns and
paradigms. Nat. Rev. Genet. 10,
295–304. doi: 10.1038/nrg2540
Chai, L., Liu, S., Mao, Q., Wang, D.,
Li, X., Zheng, X., et al. (2012). A
novel conditionally replicating aden-
oviral vector with dual expression of
IL-24 and arresten inserted in E1 and
the region between E4 and ﬁber for
improved melanoma therapy. Can-
cer Gene Ther. 19, 247–254. doi:
10.1038/cgt.2011.84
Chang, H. M., Paulson, M., Holko,
M., Rice, C. M., Williams, B.
R., Marie, I., et al. (2004). Induc-
tion of interferon-stimulated gene
expression and antiviral responses
require protein deacetylase activity.
Proc. Natl. Acad. Sci. U.S.A. 101,
9578–9583. doi: 10.1073/pnas.04005
67101
Chen, Q., Denard, B., Huang, H., and
Ye, J. (2013). Epigenetic silencing of
antiviral genes renders clones of Huh-
7 cells permissive for hepatitis C virus
replication. J. Virol. 87, 659–665. doi:
10.1128/jvi.01984-12
Chiocca, E.A. (2008). The host response
to cancer virotherapy. Curr. Opin.
Mol. Ther. 10, 38–45.
Cho,H., Proll, S. C., Szretter, K. J., Katze,
M. G., Gale, M., and Diamond, M.
S. (2013). Differential innate immune
response programs in neuronal sub-
types determine susceptibility to
Frontiers in Genetics | Epigenomics and Epigenetics September 2013 | Volume 4 | Article 184 | 8
“fgene-04-00184” — 2013/9/19 — 9:59 — page 9 — #9
Forbes et al. Tumor epigenetics in oncolytic virotherapy
infection in the brain by positive-
stranded RNA viruses. Nat. Med. 19,
458–464. doi: 10.1038/nm.3108
Chou, S. D. (2005). Histone acetylation
regulates the cell type speciﬁc CIITA
promoters, MHC class II expression
and antigen presentation in tumor
cells. Int. Immunol. 17, 1483–1494.
doi: 10.1093/intimm/dxh326
De Carvalho, D. D., Sharma, S.,
You, J. S., Su, S. F., Taberlay,
P. C., Kelly, T. K., et al. (2012).
DNA methylation screening identi-
ﬁes driver epigenetic events of cancer
cell. Cancer Cell 21, 655–667. doi:
10.1016/j.ccr.2012.03.045
Diallo, J. S., Le Boeuf, F., Lai, F.,
Cox, J., Vaha-Koskela, M., Abdel-
bary, H., et al. (2010). A high-
throughput pharmacoviral approach
identiﬁes novel oncolytic virus sensi-
tizers. Mol. Ther. 18, 1123–1129. doi:
10.1038/mt.2010.67
Diaz, R. M., Galivo, F., Kottke, T.,
Wongthida, P., Qiao, J., Thompson,
J., et al. (2007). Oncolytic immunovi-
rotherapy for melanoma using vesic-
ular stomatitis virus. Cancer Res.
67, 2840–2848. doi: 10.1158/0008-
5472.can-06-3974
Dock, G. (1904). The inﬂuence of com-
plicating diseases upon leukemia.
Am. J. Med. Sci. 127, 563–592.
Dunn, G. P., Koebel, C. M., and
Schreiber, R. D. (2006). Interferons,
immunity, and cancer immunoedit-
ing. Nat. Rev. Immunol. 6, 836–848.
doi: 10.1038/nri1961
Dunn, G. P., Sheehan, K. C., Old, L.
J., and Schreiber, R. D. (2005). IFN
unresponsiveness in LNCaP cells due
to the lack of JAK1 gene expres-
sion. Cancer Res. 65, 3447–3453. doi:
10.1158/0008-5472.can-04-4316
Egger, G., Liang, G., Aparicio, A., and
Jones, P. A. (2004). Epigenetics in
human disease and prospects for epi-
genetic therapy. Nature 429, 457–463.
doi: 10.1038/nature02625
Fang, T. C., Schaefer, U., Mecklen-
brauker, I., Stienen, A., Dewell, S.,
Chen, M. S., et al. (2012). Histone
H3 lysine 9 di-methylation as an epi-
genetic signature of the interferon
response. J. Exp. Med. 209, 661–669.
doi: 10.1084/jem.20112343
Farassati, F., Yang, A. D., and Lee, P.
W. (2001). Oncogenes in Ras sig-
nalling pathway dictate host-cell per-
missiveness to herpes simplex virus
1. Nat. Cell Biol. 3, 745–750. doi:
10.1038/35087061
Fridman, A. L., Tang, L., Kulaeva, O.
I., Ye, B., Li, Q., Nahhas, F., et al.
(2006). Expression proﬁling identi-
ﬁes three pathways altered in cellu-
lar immortalization: interferon, cell
cycle, and cytoskeleton. J. Gerontol. A
Biol. Sci. Med. Sci. 61, 879–889. doi:
10.1093/gerona/61.9.879
Fritz, V., and Fajas, L. (2010).
Metabolism and proliferation share
common regulatory pathways in can-
cer cells. Oncogene 29, 4369–4377.
doi: 10.1038/onc.2010.182
Galanis, E., Markovic, S. N., Suman,
V. J., Nuovo, G. J., Vile, R. G.,
Kottke, T. J., et al. (2012). Phase
II trial of intravenous adminis-
tration of Reolysin(®) (Reovirus
Serotype-3-dearing Strain) in
patients with metastatic melanoma.
Mol. Ther. 20, 1998–2003. doi:
10.1038/mt.2012.146
Génin, P., Morin, P., and Civas, A.
(2003). Impairment of interferon-
induced IRF-7 gene expression due
to inhibition of ISGF3 formation by
trichostatin A. J. Virol. 77, 7113–
7119. doi: 10.1128/JVI.77.12.7113-
7119.2003
Glasspool, R. M., Teodoridis, J. M.,
and Brown, R. (2006). Epigenet-
ics as a mechanism driving poly-
genic clinical drug resistance. Br.
J. Cancer 94, 1087–1092. doi:
10.1038/sj.bjc.6603024
Gomez, J. A., Wapinski, O. L., Yang,
Y. W., Bureau, J.-F., Gopinath,
S., Monack, D. M., et al. (2013).
The NeST long ncRNA controls
microbial susceptibility and epige-
netic activation of the interferon-
γ locus. Cell 152, 743–754. doi:
10.1016/j.cell.2013.01.015
Hacker, S., Dittrich, A., Mohr,
A., Schweitzer, T., Rutkowski, S.,
Krauss, J., et al. (2009). His-
tone deacetylase inhibitors cooperate
with IFN-gamma to restore caspase-
8 expression and overcome TRAIL
resistance in cancers with silencing of
caspase-8. Oncogene 28, 3097–3110.
doi: 10.1038/onc.2009.161
Hatziapostolou, M., and Iliopoulos, D.
(2011). Epigenetic aberrations dur-
ing oncogenesis. Cell. Mol. Life. Sci.
68, 1681–1702. doi: 10.1007/s00018-
010-0624-z
Heo, J., Reid, T., Ruo, L., Breit-
bach, C. J., Rose, S., Bloomston,
M., et al. (2013). Randomized dose-
ﬁnding clinical trial of oncolytic
immunotherapeutic vaccinia JX-594
in liver cancer. Nat. Med. 19, 329–
336. doi: 10.1038/nm.3089
Holling, T. M., Bergevoet, M. W., Wil-
son, L., Van Eggermond, M. C.,
Schooten, E., Steenbergen, R.D., et al.
(2007). A role for EZH2 in silencing
of IFN-gamma inducible MHC2TA
transcription in uveal melanoma. J.
Immunol. 179, 5317–5325.
Hoti, N., Chowdhury, W., Hsieh, J.
T., Sachs, M. D., Lupold, S. E., and
Rodriguez, R. (2006). Valproic acid,
a histone deacetylase inhibitor, is an
antagonist for oncolytic adenoviral
gene therapy. Mol. Ther. 14, 768–778.
doi: 10.1016/j.ymthe.2006.07.009
Huang, P. Y., Guo, J. H., and Hwang,
L. H. (2012). Oncolytic Sindbis virus
targets tumors defective in the inter-
feron response and induces signiﬁ-
cant bystander antitumor immunity
in vivo. Mol. Ther. 20, 298–305. doi:
10.1038/mt.2011.245
Hurtubise, A., Bernstein, M. L., and
Momparler, R. L. (2008). Preclin-
ical evaluation of the antineoplas-
tic action of 5-aza-2′-deoxycytidine
and different histone deacetylase
inhibitors on human Ewing’s sar-
coma cells. Cancer Cell Int. 8, 16. doi:
10.1186/1475-2867-8-16
Jain, R. K. (2005). Normalization
of tumor vasculature: an emerging
concept in antiangiogenic therapy.
Science 307, 58–62. doi: 10.1126/
science.1104819
Janson, P. C., Marits, P., Thorn,
M., Ohlsson, R., and Winqvist,
O. (2008). CpG methylation of
the IFNG gene as a mechanism
to induce immunosuppression [cor-
rection of immunosupression] in
tumor-inﬁltrating lymphocytes. J.
Immunol. 181, 2878–2886.
Johnsen, A. K., Templeton, D. J., Sy, M.,
and Harding, C.V. (1999). Deﬁciency
of transporter for antigen presen-
tation (TAP) in tumor cells allows
evasion of immune surveillance and
increases tumorigenesis. J. Immunol.
163, 4224–4231.
Johnsson, A., Durand-Dubief, M., Xue-
Franzen, Y., Ronnerblad, M., Ekwall,
K., and Wright, A. (2009). HAT-
HDAC interplay modulates global
histone H3K14 acetylation in gene-
coding. EMBO Rep. 10, 1009–1014.
doi: 10.1038/embor.2009.127
Kanaseki, T., Ikeda, H., Takamura, Y.,
Toyota, M., Hirohashi, Y., Tokino, T.,
et al. (2003). Histone deacetylation,
but not hypermethylation, modiﬁes
class II transactivator and MHC class
II gene expression in squamous cell
carcinomas. J. Immunol. 170, 4980–
4985.
Karpf, A. R., Peterson, P. W., Rawl-
ins, J. T., Dalley, B. K., Yang,
Q., Albertson, H., et al. (1999).
Inhibition of DNA methyltransferase
stimulates the expression of signal
transducer and activator of tran-
scription 1, 2, and 3 genes in
colon tumor cells. Proc. Natl. Acad.
Sci. U.S.A. 96, 14007–14012. doi:
10.1073/pnas.96.24.14007
Katsura, T., Iwai, S., Ota, Y.,
Shimizu, H., Ikuta, K., and
Yura, Y. (2009). The effects of
trichostatin A on the oncolytic
ability of herpes simplex virus for
oral squamous cell carcinoma cells.
Cancer Gene Ther. 16, 237–245. doi:
10.1038/cgt.2008.81
Kelly, E., and Russell, S. J. (2007). His-
tory of oncolytic viruses: genesis to
genetic engineering. Mol. Ther. 15,
651–659. doi: 10.1038/sj.mt.6300108
Khan, A. N., Magner, W., and Tomasi,
T. (2004). An epigenetically altered
tumor cell vaccine. Cancer Immunol.
Immunother. 53, 748–754. doi:
10.1007/s00262-004-0513-0
Khan, A. N. H., Magner, W. J., and
Tomasi, T. B. (2007). An epigenetic
vaccine model active in the preven-
tion and treatment of melanoma. J.
Transl. Med. 5, 64. doi: 10.1186/1479-
5876-5-64
Klampfer, L., Huang, J., Swaby,
L. A., and Augenlicht, L. (2004).
Requirement of histone deacetylase
activity for signaling by STAT1. J.
Biol. Chem. 279, 30358–30368. doi:
10.1074/jbc.M401359200
Krecmerova, M., and Otmar, M.
(2012). 5-azacytosine compounds
in medicinal chemistry: current
stage and future perspectives. Future
Med. Chem. 4, 991–1005. doi:
10.4155/fmc.12.36
Kulaeva, O. I., Draghici, S., Tang, L.,
Kraniak, J. M., Land, S. J., and
Tainsky, M. A. (2003). Epigenetic
silencing of multiple interferon path-
way genes after cellular immortaliza-
tion. Oncogene 22, 4118–4127. doi:
10.1038/sj.onc.1206594
Lange, S., Lampe, J., Bossow, S., Zim-
mermann, M., Neubert, W., Bitzer,
M., et al. (2013). A novel armed
oncolytic measles vaccine virus for
the treatment of cholangiocarci-
noma. Hum. Gene Ther. 24, 554–564.
doi: 10.1089/hum.2012.136
Lee, J., Goh, S.-H., Song, N., Hwang, J.-
A., Nam, S., Choi, I. J., et al. (2012).
Overexpression of IFITM1 has clini-
copathologic effects on gastric cancer
and is regulated by an epigenetic
mechanism. Am. J. Pathol. 181,
43–52. doi: 10.1016/j.ajpath.2012.
03.027
Lee, K. Y., Geng, H., Ng, K. M., Yu, J.,
Van Hasselt, A., Cao, Y., et al. (2008).
Epigenetic disruption of interferon-
γ response through silencing the
tumor suppressor interferon regu-
latory factor 8 in nasopharyngeal,
esophageal, and multiple other carci-
nomas. Oncogene 27, 5267–5276. doi:
10.1038/onc.2008.147
LeibundGut-Landmann, S., Wald-
burger, J.-M., Krawczyk, M., Otten,
L. A., Suter, T., Fontana, A., et al.
(2004). Mini-review: speciﬁcity and
expression of CIITA, the master reg-
ulator of MHC class II genes. Eur.
www.frontiersin.org September 2013 | Volume 4 | Article 184 | 9
“fgene-04-00184” — 2013/9/19 — 9:59 — page 10 — #10
Forbes et al. Tumor epigenetics in oncolytic virotherapy
J. Immunol. 34, 1513–1525. doi:
10.1002/eji.200424964
Lemay, C. G., Rintoul, J. L., Kus,
A., Paterson, J. M., Garcia, V.,
Falls, T. J., et al. (2012). Harnessing
oncolytic virus-mediated antitumor
immunity in an infected cell vac-
cine. Mol. Ther. 20, 1791–1799. doi:
10.1038/mt.2012.128
Li, K., Markosyan, R. M., Zheng,
Y. M., Golfetto, O., Bungart, B.,
Li, M., et al. (2013). IFITM pro-
teins restrict viral membrane hemi-
fusion. PLoS Pathog. 9:e1003124. doi:
10.1371/journal.ppat.1003124
Li, Q., Tang, L., Roberts, P. C., Kraniak,
J. M., Fridman, A. L., Kulaeva, O.
I., et al. (2008). Interferon regulatory
factors IRF5 and IRF7 inhibit growth
and induce senescence in immortal
Li-Fraumeni ﬁbroblasts. Mol. Cancer
Res. 6, 770–784. doi: 10.1158/1541-
7786.mcr-07-0114
Liikanen, I., Monsurro, V., Ahtiainen,
L., Raki, M., Hakkarainen, T., Dia-
conu, I., et al. (2011). Induction
of interferon pathways mediates in
vivo resistance to oncolytic aden-
ovirus. Mol. Ther. 19, 1858–1866. doi:
10.1038/mt.2011.144
Londhe, P., Zhu, B., Abraham, J., Keller,
C., and Davie, J. (2012). CIITA is
silenced by epigenetic mechanisms
that prevent the recruitment of trans-
activating factors in rhabdomyosar-
coma cells. Int. J. Cancer 131, E437–
E448. doi: 10.1002/ijc.26478
Lubieniecka, J. M., De Bruijn, D.
R., Su, L., Van Dijk, A. H.,
Subramanian, S., Van De Rijn,
M., et al. (2008). Histone deacety-
lase inhibitors reverse SS18-SSX-
mediated polycomb silencing of
the tumor suppressor early growth
response 1 in synovial sarcoma.
Cancer Res. 68, 4303–4310. doi:
10.1158/0008-5472.can-08-0092
Lund, P., Kotova, I., Kedinger, V.,
Khanwalkar, H., Voltz, E., Hahn, W.
C., et al. (2011). Transformation-
dependent silencing of tumor-
selective apoptosis-inducing TRAIL
by DNA hypermethylation is
antagonized by decitabine. Mol.
Cancer Ther. 10, 1611–1623. doi:
10.1158/1535-7163.MCT-11-0140
MacTavish, H., Diallo, J. S., Huang,
B., Stanford, M., Le Boeuf,
F., De Silva, N., et al. (2011).
Enhancement of vaccinia virus
based oncolysis with histone
deacetylase inhibitors. PLoS ONE
5:e14462. doi: 10.1371/journal.pone.
0014462
Magnani, L., Eeckhoute, J., and
Lupien, M. (2011). Pioneer factors:
directing transcriptional regulators
within the chromatin environment.
Trends Genet. 27, 465–474. doi:
10.1016/j.tig.2011.07.002
Magnani, L., Stoeck, A., Zhang,
X., Lanczky, A., Mirabella, A.
C., Wang, T. L., et al. (2013).
Genome-wide reprogramming of
the chromatin landscape under-
lies endocrine therapy resistance in
breast cancer. Proc. Natl. Acad.
Sci. U.S.A. 110, E1490–E1499. doi:
10.1073/pnas.1219992110
Maldonado, A. R., Klanke, C., Jegga,
A. G., Aronow, B. J., Mahller,
Y. Y., Cripe, T. P., et al. (2010).
Molecular engineering and valida-
tion of an oncolytic herpes simplex
virus type 1 transcriptionally tar-
geted to midkine-positive tumors.
J. Gene Med. 12, 613–623. doi:
10.1002/jgm.1479
Meissner, M., Whiteside, T. L., Van
Kuik-Romein, P., Valesky, E. M.,
Van Den Elsen, P. J., Kaufmann,
R., et al. (2008). Loss of interferon-
γ inducibility of the MHC class
II antigen processing pathway in
head and neck cancer: evidence for
post-transcriptional as well as epi-
genetic regulation. Br. J. Dermatol.
158, 930–940. doi: 10.1111/j.1365-
2133.2008.08465.x
Merrick, A. E., Ilett, E. J., and Melcher,
A. A. (2009). JX-594, a targeted
oncolytic poxvirus for the treatment
of cancer. Curr. Opin. Investig. Drugs
10, 1372–1382.
Morimoto, Y., Toyota, M., Satoh, A.,
Murai, M., Mita, H., Suzuki, H.,
et al. (2004). Inactivation of class II
transactivator by DNA methylation
and histone deacetylation associated
with absence of HLA-DR induction
by interferon-γ in haematopoietic
tumour cells. Br. J. Cancer 90, 844–
852. doi: 10.1038/sj.bjc.6601602
Morris, A. C., Spangler,W. E., and Boss,
J. M. (2000). Methylation of class II
trans-activator promoter IV: a novel
mechanism of MHC class II gene
control. J. Immunol. 164, 4143–4149.
Muhlethaler-Mottet, A., Di Berardino,
W., Otten, L. A., and Mach, B.
(1998). Activation of the MHC
class II transactivator CIITA by
interferon-gamma requires coopera-
tive interaction between Stat1 and
USF-1. Immunity 8, 157–166. doi:
10.1016/S1074-7613(00)80468-9
Muntean, A. G., and Hess, J. L. (2009).
Epigenetic dysregulation in cancer.
Am. J. Pathol. 175, 1353–1361. doi:
10.2353/ajpath.2009.081142
Naka, K., Abe, K., Takemoto, K.,
Dansako, H., Ikeda, M., Shimotohno,
K., et al. (2006). Epigenetic silenc-
ing of interferon-inducible genes is
implicated in interferon resistance of
hepatitis C virus replicon-harboring
cells. J. Hepatol. 44, 869–878. doi:
10.1016/j.jhep.2006.01.030
Nguyen, T. L., Abdelbary, H., Arguello,
M., Breitbach, C., Leveille, S., Diallo,
J. S., et al. (2008). Chemical target-
ing of the innate antiviral response
by histone deacetylase inhibitors ren-
ders refractory cancers sensitive to
viral oncolysis. Proc. Natl. Acad.
Sci. U.S.A. 105, 14981–14986. doi:
10.1073/pnas.0803988105
Norman, K., and Lee, P. (2000).
Reovirus as a novel oncolytic agent.
J. Clin. Invest. 105, 1035–1038. doi:
10.1172/JCI9871
Nusinzon, I., and Horvath, C. M.
(2003). Interferon-stimulated tran-
scription and innate antiviral immu-
nity require deacetylase activity and
histone deacetylase 1. Proc. Natl.
Acad. Sci. U.S.A. 100, 14742–14747.
doi: 10.1073/pnas.2433987100
Okemoto, K., Wagner, B. P., Haseley, A.
M., Price, R. L., Kaur, B., andChiocca,
A. E. (2012). 5-Azacitydine augments
the anti-glioma efﬁcacy of Herpes-
based oncolytic virotherapy. AACR
103rd Annual Meeting 2012: Cancer
Research, Chicago.
Otsuki, A., Patel, A., Kasai, K., Suzuki,
M., Kurozumi, K., Antonio Chiocca,
E., et al. (2008). Histone deacety-
lase inhibitors augment antitumor
efﬁcacy of herpes-based oncolytic
viruses. Mol. Ther. 16, 1546–1555.
doi: 10.1038/mt.2008.155
Parato, K. A., Senger, D., Forsyth, P. A.,
and Bell, J. C. (2005). Recent progress
in the battle between oncolytic
viruses and tumours. Nat. Rev. Can-
cer 5, 965–976. doi: 10.1038/nrc1750
Patel, N., Black, J., Chen, X.,Marcondes,
A. M., Grady, W. M., Lawlor, E. R.,
et al. (2012). DNA methylation and
gene expression proﬁling of ewing
sarcoma primary tumors reveal genes
that are potential targets of epigenetic
inactivation. Sarcoma 2012, 498472.
doi: 10.1155/2012/498472
Peserico, A., and Simone, C. (2010).
Physical and functional HAT/HDAC
interplay regulates protein acetyla-
tion balance. J. Biomed. Biotechnol.
2011, 371832.
Pol, J., Le Boeuf, F., and Diallo, J.
S. (2013). [Genetic, immunologi-
cal, and pharmacological strategies to
generate improvedoncolytic viruses].
Med. Sci. (Paris) 29, 165–173. doi:
10.1051/medsci/2013292014
Pulido, J., Kottke, T., Thompson, J.,
Galivo, F., Wongthida, P., Diaz,
R. M., et al. (2012). Using virally
expressed melanoma cDNA libraries
to identify tumor-associated antigens
that cure melanoma. Nat. Biotech-
nol. 30, 337–343. doi: 10.1038/nbt.
2157
Radosevich, M., Jager, M., and Ono, S.
J. (2007). Inhibition of MHC class II
gene expression in uveal melanoma
cells is due to methylation of the
CIITA gene or an upstream activa-
tor. Exp. Mol. Pathol. 82, 68–76. doi:
10.1016/j.yexmp.2006.03.005
Reu, F. J., Bae, S. I., Cherkassky, L., Lea-
man, D. W., Lindner, D., Beaulieu,
N., et al. (2006a). Overcoming resis-
tance to interferon-induced apopto-
sis of renal carcinoma and melanoma
cells by DNA demethylation. J.
Clin. Oncol. 24, 3771–3779. doi:
10.1200/jco.2005.03.4074
Reu, F. J., Leaman, D. W., Maitra, R.
R., Bae, S. I., Cherkassky, L., Fox,
M. W., et al. (2006b). Expression of
RASSF1A, an epigenetically silenced
tumor suppressor, overcomes resis-
tance to apoptosis induction by inter-
ferons. Cancer Res. 66, 2785–2793.
doi: 10.1158/0008-5472.can-05-2303
Rice, J. C., and Allis, C. D. (2001).
Histone methylation versus histone
acetylation: new insights into epige-
netic regulation. Curr. Opin. Cell Biol.
13, 263–273. doi: 10.1016/S0955-
0674(00)00208-8
Russell, S. J., Peng, K. W., and Bell,
J. C. (2012). Oncolytic virotherapy.
Nat. Biotechnol. 30, 658–670. doi:
10.1038/nbt.2287
Sakamoto, S., Potla, R., and Larner, A.
C. (2004). Histone deacetylase activ-
ity is required to recruit RNA poly-
merase II to the promoters of selected
interferon-stimulated early response
genes. J. Biol. Chem. 279, 40362–
40367. doi: 10.1074/jbc.M406400200
Satoh, A., Toyota, M., Ikeda, H., Mori-
moto, Y., Akino, K., Mita, H., et al.
(2004). Epigenetic inactivation of
class II transactivator (CIITA) is asso-
ciated with the absence of interferon-
γ-induced HLA-DR expression in
colorectal and gastric cancer cells.
Oncogene 23, 8876–8886. doi:
10.1038/sj.onc.1208144
Schenk, T., Chen, W. C., Gollner,
S., Howell, L., Jin, L., Hebestreit,
K., et al. (2012). Inhibition of the
LSD1 (KDM1A) demethylase reacti-
vates the all-trans-retinoic acid dif-
ferentiationpathway in acutemyeloid
leukemia.Nat.Med. 18, 605–611. doi:
10.1038/nm.2661
Schildhaus, H.-U., Riegel, R., Hart-
mann, W., Steiner, S., Wardel-
mann, E., Merkelbach-Bruse, S., et al.
(2011). Lysine-speciﬁc demethylase
1 is highly expressed in solitary
ﬁbrous tumors, synovial sarcomas,
rhabdomyosarcomas, desmoplastic
small round cell tumors, and malig-
nant peripheral nerve sheath tumors.
Hum. Pathol. 42, 1667–1675. doi:
10.1016/j.humpath.2010.12.025
Frontiers in Genetics | Epigenomics and Epigenetics September 2013 | Volume 4 | Article 184 | 10
“fgene-04-00184” — 2013/9/19 — 9:59 — page 11 — #11
Forbes et al. Tumor epigenetics in oncolytic virotherapy
Setiadi, A. F., David, M. D., Seipp, R.
P., Hartikainen, J. A., Gopaul, R.,
and Jefferies, W. A. (2007). Epige-
netic control of the immune escape
mechanisms in malignant carcino-
mas. Mol. Cell. Biol. 27, 7886–7894.
doi: 10.1128/mcb.01547-07
Shmulevitz, M., Marcato, P., and Lee,
P. W. (2005). Unshackling the links
between reovirus oncolysis, Ras sig-
naling, translational control and can-
cer. Oncogene 24, 7720–7728. doi:
10.1038/sj.onc.1209041
Sobol, P. T., Boudreau, J. E., Stephen-
son, K., Wan, Y., Lichty, B. D.,
and Mossman, K. L. (2011). Adap-
tive antiviral immunity is a deter-
minant of the therapeutic success
of oncolytic virotherapy. Mol. Ther.
19, 335–344. doi: 10.1038/mt.2010.
264
Soncini, M., Santoro, F., Gutierrez,
A., Frige, G., Romanenghi, M.,
Botrugno, O. A., et al. (2013).
The DNA demethylating agent
decitabine activates the TRAIL
pathway and induces apoptosis in
acute myeloid leukemia. Biochim.
Biophys. Acta 1832, 114–120. doi:
10.1016/j.bbadis.2012.10.001
Stephenson, K. B., Barra, N. G.,
Davies, E., Ashkar, A. A., and Lichty,
B. D. (2012). Expressing human
interleukin-15 from oncolytic vesic-
ular stomatitis virus improves sur-
vival in a murine metastatic colon
adenocarcinoma model through the
enhancement of anti-tumor immu-
nity. Cancer Gene Ther. 19, 238–246.
doi: 10.1038/cgt.2011.81
Stojdl, D. F., Lichty, B., Knowles,
S., Marius, R., Atkins, H., Sonen-
berg, N., et al. (2000). Exploit-
ing tumor-speciﬁc defects in the
interferon pathway with a previ-
ously unknown oncolytic virus. Nat.
Med. 6, 821–825. doi: 10.1038/
77558
Stojdl, D. F., Lichty, B. D., Teno-
ever, B. R., Paterson, J. M.,
Power, A. T., Knowles, S., et al.
(2003). VSV strains with defects
in their ability to shutdown innate
immunity are potent systemic anti-
cancer agents. Cancer Cell 4, 263–
275. doi: 10.1016/S1535-6108(03)00
241-1
Suh, H.-S., Choi, S., Khattar, P.,
Choi, N., and Lee, S. C. (2010).
Histone deacetylase inhibitors sup-
press the expression of inﬂamma-
tory and innate immune response
genes in human microglia and astro-
cytes. J. Neuroimmune Pharmacol. 5,
521–532. doi: 10.1007/s11481-010-
9192-0
Suva, M. L., Riggi, N., and Bern-
stein, B. E. (2013). Epigenetic repro-
gramming in cancer. Science 339,
1567–1570. doi: 10.1126/science.123
0184
Taylor, B. S., Decarolis, P. L., Ange-
les, C. V., Brenet, F., Schultz, N.,
Antonescu, C. R., et al. (2011).
Frequent alterations and epigenetic
silencing of differentiation path-
way genes in structurally rearranged
liposarcomas. Cancer Discov. 1, 587–
597. doi: 10.1158/2159-8290.cd-11-
0181
Truax, A. D., Thakkar, M., and
Greer, S. F. (2012). Dysregulated
recruitment of the histone methyl-
transferase EZH2 to the class II
transactivator (CIITA) promoter IV
in breast cancer cells. PLoS ONE
7:e36013. doi: 10.1371/journal.pone.
0036013
Vigneau, S., Levillayer, F., Crespeau,
H., Cattolico, L., Caudron, B.,
Bihl, F., et al. (2001). Homology
between a 173-kb region from mouse
chromosome 10, telomeric to the
Ifng locus, and human chromosome
12q15. Genomics 78, 206–213. doi:
10.1006/geno.2001.6656
Watanabe, T., Hioki, M., Fujiwara,
T., Nishizaki, M., Kagawa, S., Taki,
M., et al. (2006). Histone deacety-
lase inhibitor FR901228 enhances
the antitumor effect of telomerase-
speciﬁc replication-selective aden-
oviral agent OBP-301 in human lung
cancer cells. Exp. Cell Res. 312, 256–
265.
U.S. National Library of Medicine
(2013). ClinicalTrials.gov [Online].
Available at: www.clinicaltrials.gov
[accessed January 29, 2013].
Yamashita, M., Toyota, M., Suzuki, H.,
Nojima, M., Yamamoto, E., Kami-
mae, S., et al. (2010). DNA methy-
lation of interferon regulatory factors
in gastric cancer and non-cancerous
gastric mucosae. Cancer Sci. 101,
1708–1716. doi: 10.1111/j.1349-
7006.2010.01581.x
Yoo, C. B., and Jones, P. A. (2006).
Epigenetic therapy of cancer: past,
present, and future. Nat. Rev. Drug
Discov. 5, 37–50. doi: 10.1038/nr
d1930
Yu, F., Ng, S. S., Chow, B.
K., Sze, J., Lu, G., Poon, W.
S., et al. (2011). Knockdown of
interferon-induced transmembrane
protein 1 (IFITM1) inhibits prolif-
eration, migration, and invasion of
glioma cells. J. Neurooncol. 103, 187–
195. doi: 10.1007/s11060-010-0377-4
Conflict of Interest Statement: John C.
Bell is CSO and co-founder of Jennerex
Biotherapeutics.
Received: 03 May 2013; paper pend-
ing published: 18 June 2013; accepted:
29 August 2013; published online: 20
September 2013.
Citation: ForbesNE,AbdelbaryH,Lupien
M,Bell JC, andDiallo J-S (2013) Exploit-
ing tumor epigenetics to improve oncolytic
virotherapy. Front. Genet. 4:184. doi:
10.3389/fgene.2013.00184
This article was submitted to Epigenomics
and Epigenetics, a section of the journal
Frontiers in Genetics.
Copyright © 2013 Forbes, Abdelbary,
Lupien, Bell and Diallo. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) or licensor
are credited and that the original publica-
tion in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
www.frontiersin.org September 2013 | Volume 4 | Article 184 | 11
